Physician profile
Harry Sandoval Yu
NPI 1689697880
$6,936.93
in general payments reported to CMS, 2019-2025
38 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $218 · 2022: $735 · 2023: $1,887 · 2024: $3,192 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,694 · Long Term Medical Supply Or Device Loan: $1,363 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.59 |
| Long Term Medical Supply Or Device Loan | $1,363.06 |
| Education | $288.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,656.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $727.72 | 2023-2024 | Imfinzi, Enhertu, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $540.99 | 2019-2024 | Opdualag, Opdivo |
| Incyte Corporation | $348.96 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $337.53 | 2023-2024 | Libtayo |
| Seagen INC. | $295.62 | 2022-2023 | Adcetris |
| Celgene Corporation | $275.64 | 2019-2024 | Reblozyl |
| Lilly USA, LLC | $271.37 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Merck Sharp & Dohme LLC | $259.66 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $224.22 | 2019-2024 | Carvykti, Darzalex, Tecvayli |
| Novocure Gmbh | $200.00 | 2022 | |
| Genentech USA, INC. | $190.78 | 2019-2024 | Hemlibra, Tecentriq, Lunsumio |
| Amgen INC. | $184.87 | 2020-2025 | Actimmune, Vectibix, Nplate |
| Pfizer INC. | $151.45 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $150.17 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $138.64 | 2023-2024 | Ninlaro |
| Karyopharm Therapeutics INC. | $126.25 | 2023-2024 | Xpovio |
| Sobi, INC | $124.40 | 2024 | |
| Agios Pharmaceuticals, INC. | $112.47 | 2019 | |
| Eisai INC. | $76.61 | 2023 | |
| Abbvie INC. | $73.53 | 2024 | |
| Astellas Pharma US INC | $64.39 | 2023-2024 | Xtandi |
| Glaxosmithkline, LLC. | $43.82 | 2023-2024 | Jemperli, Zejula, Ojjaara |
| Genzyme Corporation | $39.04 | 2023-2024 | |
| Array Biopharma INC | $38.51 | 2023-2024 | Xalkori, Lorbrena, Mektovi |
| Daiichi Sankyo INC. | $29.50 | 2024 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.01 | 2023 | Gilotrif |
| Taiho Oncology, INC. | $24.62 | 2024 | |
| Coherus Oncology, INC. | $22.31 | 2024 | |
| Beigene USA, INC. | $21.96 | 2023 | Brukinsa |
| Emd Serono, INC. | $21.80 | 2024 | |
| Deciphera Pharmaceuticals INC. | $21.55 | 2023 | Qinlock |
| Mirati Therapeutics, INC. | $21.54 | 2023 | Krazati |
| Novo Nordisk INC | $21.50 | 2023 | Rebinyn |
| Aadi Bioscience, INC. | $19.61 | 2023 | Fyarro |
| Bayer Healthcare Pharmaceuticals INC. | $19.49 | 2023 | |
| Novocure INC. | $15.74 | 2024 | Optune |
| Gilead Sciences, INC. | $14.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.